Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | TSHR | P16473 | 1/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.77 |
| ▸ | AR | P10275 | 2/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7165606 | 0.93 | SIGMAR1 (0.70) | SIGMAR1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL7165607 | 0.93 | SIGMAR1 (0.70) | SIGMAR1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL23252258 | 0.81 | AR (0.80) | SIGMAR1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL18061529 | 0.81 | AR (0.80) | SIGMAR1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL23252259 | 0.81 | AR (0.80) | SIGMAR1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15314418 | 0.79 | SIGMAR1 (0.73) | SIGMAR1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL15314413 | 0.79 | SIGMAR1 (0.73) | SIGMAR1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL870758 | 0.78 | SIGMAR1 (0.76) | SIGMAR1HRH3 | |
| SCHEMBL10123280 | 0.78 | SIGMAR1 (0.76) | SIGMAR1HRH3 | |
| SCHEMBL24564652 | 0.78 | KMT2A (0.57) | SIGMAR1ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544996-B2 | A substituted or unsubstituted phenyl-(4-trans-2-phenylcyclopropyl)methylpiperazine compounds or salt useful for treating brain disorders such as schizophrenia, Parkinson, dementia, depression and anxiety | NEUROGEN CORPORATION | 2003-04-08 | — | — | US | disclosed |
| US-20020022630-A1 | 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands | NEUROGEN CORPORATION | 2002-02-21 | — | — | US | disclosed |
| US-6284761-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022630-A1 | 1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands | DRD2, DRD4, PARK7 | SIGMAR1 57/4885ALDH1A1 391/4885LMNA 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.